Moleculin Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

Related Keywords

United Kingdom ,Houston ,Texas ,United States ,British ,Liposomal Annamycin ,Walter Klemp ,Jenene Thomas ,Exchange Commission ,Moleculin Biotech Inc ,Prnewswire Moleculin Biotech Inc ,Facebook ,Securities Exchange ,Nasdaq ,Twitter ,Shareholder Intelligence Services ,British Journal Of Cancer Research ,Linkedin ,Released Clinical Trial Update ,Chief Executive Officer ,Moleculin Provides Update ,Ongoing Clinical Trials ,Outlines Expected Upcoming Milestones ,European Phase ,After Induction Therapy ,British Journal ,Financial Results ,Second Quarter ,Moleculin Biotech Conference ,Moleculin Biotech ,Transcription Modulator ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Condensed Consolidated Statements ,Months Ended June ,